Страна: Канада
Язык: английский
Источник: Health Canada
LISINOPRIL
RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED
C09AA03
LISINOPRIL
10MG
TABLET
LISINOPRIL 10MG
ORAL
100/500
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0121550001; AHFS:
CANCELLED POST MARKET
2014-09-19
_ _ _ratio-LISINOPRIL Z 5 mg, 10 mg and 20 mg Tablets _ _Page 1 of 39 _ PRODUCT MONOGRAPH RATIO-LISINOPRIL Z Lisinopril Tablets 5 mg, 10 mg and 20 mg USP Angiotensin Converting Enzyme Inhibitor ratiopharm inc. Canada J7J 1P3 DATE OF PREPARATION: SEPTEMBER 20, 2007 CONTROL NUMBER: 110419 _ _ _ratio-LISINOPRIL Z 5 mg, 10 mg and 20 mg Tablets _ _Page 2 of 39 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ……………………………………………………..4 ADVERSE REACTIONS................................................................................................. 10 DRUG INTERACTIONS ................................................................................................. 15 DOSAGE AND ADMINISTRATION............................................................................. 16 SYMPTOMS AND TREATMENT OF OVERDOSAGE ............................................... 19 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 19 STORAGE AND STABILITY......................................................................................... 22 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 22 PART II: SCIENTIFIC INFORMATION .............................................................................. 23 PHARMACEUTICAL INFORMATION......................................................................... 23 CLINICAL TRIALS......................................................................................................... 24 DETAILED PHARMACOLOGY............................................................... Прочитать полный документ